Subscribe To
Sensei biotherapeutics reports favorable clinical data for sns-101 at 2023 sitc annual meeting
– Clinical dose escalation data for SNS-101 monotherapy show well tolerated safety profile, potentially best-in-class pharmacokinetics, and encourag...
November 3, 2023, 8:05 pm
Actinium pharmaceuticals: the trickle down continues, and i maintain a buy
Actinium Pharmaceuticals continues to make progress with their radiolabelled CD45 antibody Iomab-B, whi...
November 3, 2023, 6:08 pm
Coherus presents data from next-generation immuno-oncology programs at 38th annual meeting of society for immunotherapy of cancer (sitc)
– Data demonstrate distinct IL-27-mediated expression of genes associated with immune suppression in vitro, supporting ongoing clinical development ...
November 3, 2023, 12:30 pm
Ibio further expands tech stack with shieldtx™; enhances immuno-oncology development pipeline with conditionally activated muc16xcd3 bispecific
– ShieldTx potentially increases safety and developability of therapeutic antibodies for difficult targets and modes of action – BRYAN, Texas and ...
November 1, 2023, 12:24 pm
Mersana therapeutics to host third quarter 2023 conference call on november 7, 2023
CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on d...
October 31, 2023, 4:30 pm
Context therapeutics reveals ‘encouraging' preclinical data for ctim-76 tumor treatment
Context Therapeutics (NASDAQ:CNTX) Inc has announced what it called encouraging preclinical data regarding its preclinical asset, CTIM-76, a Claudin 6...
October 31, 2023, 10:12 am
Acumen pharmaceuticals presents late-breaker phase 1 updates exploring novel target engagement, dosing regimen and safety findings for acu193 in early alzheimer’s disease at the 16th annual clinical t
– Acumen presented data exploring target engagement modeling of ACU193, the first clinical-stage amyloid beta oligomer (AβO)-targeting antibody, to...
October 27, 2023, 1:25 pm
Sensei biotherapeutics to present initial clinical data from dose escalation trial of sns-101 at 2023 sitc annual meeting
BOSTON, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discove...
October 25, 2023, 9:05 am
Ambrx: next-generation antibody-drug conjugates, buying the dip after esmo data
Ambrx Biopharma Inc. common stock experienced an irrational selloff following the Phase 1/2 ESMO data release for its ADC candidate ARX517, presenting...
October 24, 2023, 11:23 am
Roche enters into a definitive agreement to acquire telavant including rights to novel tl1a directed antibody (rvt-3101) for the treatment of inflammatory bowel disease from roivant
Roche will gain the rights to develop, manufacture and commercialize RVT-3101 in the US and Japan for the treatment of inflammatory bowel disease and ...
October 23, 2023, 5:00 am
Xencor: a mid-stage clinical company with falling losses
Xencor, Inc. is a biotech company focused on the development and commercialization of anticancer medications. They have successful partnerships and li...
October 20, 2023, 11:02 pm
Trending tickers: at&t, merck-daiichi sankyo, klaviyo: trending tickers october 29, 2023
Scotiabank analysts upgrade AT&T (T) stock from "Sector Perform" to "Sector Outperform." Merck (MRK) strikes a deal worth up to $22 billion with Japan...
October 20, 2023, 5:44 pm
Sanofi seeing 'unprecedented' demand for rsv therapy
French drugmaker Sanofi said on Friday it was seeing an "unprecedented level" of demand for its antibody ...
October 20, 2023, 2:31 pm
Tourmaline bio announces closing of merger with talaris therapeutics and concurrent private placement of $75 million
Tourmaline will be focused on advancing TOUR006, its differentiated anti-IL-6 antibody, to treat thyroid eye disease (TED), atherosclerotic cardiovasc...
October 19, 2023, 9:37 pm
Daiichi sankyo and merck team up on $22 bln collaboration for sankyo's antibody drug conjugates
Daiichi Sankyo and Merck have entered into an agreement worth up to $22 billion for three of Daiichi Sankyo's DXd ...
October 19, 2023, 7:46 pm
Cytomx therapeutics presents preclinical profile of epcam-directed antibody drug conjugate cx-2051 at 2023 world adc conference
– CX-2051 is tailored for treatment of EpCAM-expressing cancers by matching target expression and tumor sensitivity with a topoisomerase-1 inhibitor...
October 18, 2023, 8:30 pm
Hookipa pharma announces publication of preclinical data of hepatitis b virus (hbv) therapeutic vaccine developed in collaboration with gilead sciences
HB-400, a novel arenaviral therapeutic vaccine, generates robust T cell responses specific to hepatitis B virus with high ...
October 18, 2023, 11:01 am
Eli lilly is buying another european cancer firm mablink bioscience
Eli Lilly & Co (NYSE: LLY) is buying Mablink Bioscience – a French biotechnology company that focuses primarily on the next-generation, antibody-dru...
October 18, 2023, 10:01 am
Comera life sciences presents sqore™ platform technology data at podd: partnerships in drug delivery conference
WOBURN, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) — Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generat...
October 16, 2023, 12:00 pm
New rsv protections for infants hit cost, insurance hurdles in u.s. rollout
Pfizer's maternal vaccine, Abrysvo, and Sanofi's monoclonal antibody, Beyfortus, were approved for expectant mothers and infants in the U.S. earlier t...
October 13, 2023, 12:22 pm
